Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks
Inclusion Criteria:
Exclusion Criteria:
Huntsville, Alabama 35801, United States
Calabasas, California 91302, United States
Upland, California 91786, United States
Vero Beach, Florida 32960, United States
Philadelphia, Pennsylvania 19152, United States
Dallas, Texas 75235, United States
Buenos Aires, C1417EYG, Argentina
Quilmes, 1878, Argentina
Brisbane, Queensland 4066, Australia
Maroochydore, Queensland 4558, Australia
Elizabeth Vale, South Australia 5112, Australia
Santiago, Chile
Valdivia, Chile
Viña del Mar, Chile
Leipzig, 04103, Germany
Budapest, 1023, Hungary
Esztergom, 2500, Hungary
Kistarcsa, 2143, Hungary
Szolnok, 5000, Hungary
Hyderabaad, 400082, India
Lucknow, 226018, India
Pune, 411001, India
Secunderabad, 800003, India
Chihuahua City, 31000, Mexico
Cuernavaca, 62270, Mexico
Guadalajara, 44100, Mexico
Mexico City, 06700, Mexico
Monterrey, 64020, Mexico
San Luis Potosí City, 78210, Mexico
Tampico, 89000, Mexico
Bialystok, 15-337, Poland
Chełm Śląski, 41-403, Poland
Elblag, 82-300, Poland
Krakow, 30-510, Poland
Lubin, 20-022, Poland
Lublin, 20-954, Poland
Poznan, 60-356, Poland
Torun, 87-100, Poland
Warsaw, 02-777, Poland
Wroclaw, 50-088, Poland
Brasov, 500365, Romania
Târgu Mureş, 540136, Romania
Bratislava, 83103, Slovakia
Rimavska, 97101, Slovakia
Ivano-Frankivsk, 76018, Ukraine
Kiev, 1601, Ukraine
Odesa, 65027, Ukraine